Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bococizumab - Pfizer

Drug Profile

Bococizumab - Pfizer

Alternative Names: PF-04950615; PF-4950615; RN-316

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Halozyme Therapeutics; Pfizer
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 01 Nov 2016 Pfizer terminates the phase III SPIRE-2 trial for Cardiovascular disorders (Prevention, Adjunctive treatment) in Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Northern Ireland, Peru, Poland, Puerto Rico, Romania, Russia, Scotland, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom and USA, following the discontinuation of the global clinical development programme for bococizumab
  • 01 Nov 2016 University of California at San Francisco and Pfizer terminate the phase III B-HIVE trial for Cardiovascular disorders in USA, following the discontinuation of the global clinical development programme for bococizumab
  • 01 Nov 2016 Discontinued - Phase-I for Hypercholesterolaemia (Combination therapy, Monotherapy) in Belgium (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top